We continue our myeloma series, transitioning our discussion from autologous stem cell transplant to maintenance therapy for myeloma.
Content:
- Why do we use revlimid (lenalidomide) maintenance?
- What about in high risk patients?
- What is the role of MRD testing?
- What about daratumumab in the maintenance setting?
This episode has been sponsored by Pr ... Show More
Jul 29
Episode 158: Head and Neck Cancer Series, Pt. 1 - Introduction
This week, we kick off our Head and Neck Cancer series. Using the case of a man with a painless neck mass, we build a framework for the whole series. Content: - Why head and neck cancer is really two distinct diseases- The biology behind HPV-associated oropharyngeal cancer- How t ... Show More
26m 52s
Jul 1
Episode 157: Immune Thrombocytopenic Purpura Series, Pt 3- Challenging Scenarios in ITP
This week, we put everything we talked about in our ITP series together and talk about how we manage ITP in complicated patient scenarios. Through a case-based discussion, we discuss how to we would approach each of these complicated scenarios. If you haven’t done so already, be ... Show More
29m 16s
Jun 24
Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory
This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on t ... Show More
25m 45s
May 2022
S1 Episode 2: Frontline Therapy for Multiple Myeloma
Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/view ... Show More
23m 37s
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s
Aug 2025
S2 Episode 1: Managing Side Effects and Maximizing Quality of Life in Multiple Myeloma Patients
Joseph Mikhael, MD, and Surbhi Sidana, MD, discuss the importance of balancing treatment intervals, managing side effects, and maximizing quality of life in multiple myeloma patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.c ... Show More
23m 58s
Dec 2024
Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation
In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ... Show More
20m 5s
Jun 2022
S1 Episode 3: Addressing Comorbidities in Multiple Myeloma: Treating People, Not the Disease
Joseph Mikhael, MD, and Ashley Rosko, MD, discuss the role of comorbidities in multiple myeloma and stress the importance of shifting away from the sole use of age-based treatment decisions. Relevant disclosures can be found with the episode show notes on Medscape.com (https://ww ... Show More
20m 18s